For About $1 Per Day, You Can Get Testing, Support, And Peace of Mind.
Cancer is a complex personal genetic disease. Cancer Guardian is a transformative benefit program that can help in the prevention and management of cancer by combining the power of DNA testing with the personalized support of expert cancer resources.
First Benefit: Clinical Grade DNA Testing
Learn Your Hereditary Risk For Cancer
Why Cancer Guardian
What You Get
Advanced DNA Testing
Leverage DNA testing Innovations to prevent and combat cancer.
Preventive: Hereditary Risk Screening Test (Day 1 Benefit)
Using a simple saliva sample, this testing evaluates DNA to determine if a member may be at a higher risk for developing cancer, due to a hereditary mutation. *Requires a nonrefundable payment for 1 year of membership to receive hereditary screening test.
Post Diagnosis: Advanced DNA Testing of the Cancer
Following a cancer diagnosis, members have access to Advanced Genomic DNA Testing of their cancer, which can help identify the most effective treatment options available.
You are always supported by real people in real time with Cancer Guardian.
Cancer Information Line (Day 1 Benefit)
A member support line staffed by oncology experts who provide guidance for any cancer related topic.
Cancer Support Specialists
Following a cancer diagnosis, a Cancer Support Specialist will be assigned to provide dedicated support throughout the cancer journey.
Additionally, Cancer Guardian provides:
Expert Pathology Review
On-Site Nurse Advocate (one visit)
The cancer journey can be confusing and financially devastating.
Medical Records Platform
(Day 1 Benefit)
A cloud-based platform where members can consolidate their medical records and images for simplified viewing and secure sharing.
Clinical Trial Explorer
The Explorer program uses AI technology and experienced research oncologists to identify clinical trials the member is eligible for.
Financial Navigation Report
The Financial Navigation solution draws from a rich ecosystem of over $4 billion of public and private funds to identify financial aid and subsidies the member may qualify for.
Learn about your genes and how they impact your health with genetic information on your risk for cancer.
How It Works
Genetic and Genomic Testing
You Start with Genetic Testing which looks at inherited traits in your genes and certain cancer relevant mutations that you could have inherited from your parents. *Requires a nonrefundable payment for 1 year of membership to receive hereditary screening test”
At Diagnosis you will have a Genomic Test of your cancer. Genomic Testing detects mutations that could impact your tumor's growth and response to therapy. Mutations can be inherited or acquired over your lifetime. This testing can improve diagnostic accuracy, guide treatment selections, improve patient survival rates, and decrease wasted healthcare costs associated with misdiagnosis.
Clinical Trials and Financial Aid
Are there Clinical Trials or Financial Aid that you qualify for? Cancer Guardian helps you Navigate these opportunities.
Member And Family Benefits
In Addition to all the benefits for a Cancer Guardian Member, your children under age 26 are included in almost all benefits of the membership.
In addition, all First Degree Blood Relatives have benefits as well.
The Family Follow-Up Test Program provides testing for first-degree blood relatives if a positive mutation is reported, at no cost.
Cancer Guardian Membership is in effect.
Must be a first-degree blood relative.
Original Hereditary Test must have originated through Cancer Guardian.
Pathogenic or likely pathogenic variant was found.
Order must be placed within 90 days of the original individual's test report being issued.
1.Lifetime Risk of developing or Dying From Cancer Basic Cancer Facts American Cancer Society 2019
2.High Cost Claims and Injectable Drug Trends Sun Life Stop-Loss Research Report 2019 For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships Matthew Banegas, Gery P Guy, Janet S. de Moor Health Affairs 2019
3.Estimation of U.S. patients with cancer who may respond to cytotoxic chemotherapy Edward Maldonado, Scott Parsons Journal of Clinical Oncology 2019
4.Quality in Cancer Diagnosis Stephen S.Raab, MD, Dana M Grzbicki, MD, PhD Cancer J Clinical 2010
5.Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. Joseph M. Unger, Riha Vaidya, Dawn L. Hershman, Lori M. Minasian, Mark E. Fleury JNCI J NATL Cancer Inst 2019
6.The Spread of Medical Fake news in Social Media Przemyslaw M.Waszak, Wioleta Kasprzycka-Waszak, Alicja Kubanekd Health Policy & Technology Review – Elsevier 2018
7.Manickam et al 2018: https://www.ncbi.nlm.nih.gov/books/NBK1247